Eton Pharmaceuticals (ETON)
NASDAQ:ETON
Want to see ETON full AI Analyst Report?
Top Page
Eton Pharmaceuticals
(NASDAQ:ETON)
Select Model
Select Model
Rating:63Neutral
Price Target:
$33.00
▲(31.79% Upside)
Action:Reiterated
Date:06/10/26
ETON scores as moderately attractive primarily due to improving financial trajectory (rapid revenue scale, positive EBITDA/FCF, and reduced leverage) and a strong, guidance-raising earnings call. Technicals are supportive but not strongly overbought. The main drag is valuation optics due to ongoing GAAP losses (negative P/E) and recently softer cash-flow momentum.
Positive Factors
Revenue growth & commercial momentum
Sustained, high‑single to double‑digit revenue growth driven by new launches (DESMODA, HEMANGEOL) and stronger core sales signals scalable commercial execution. Durable revenue expansion supports reinvestment, better leverage of fixed costs, and underpins multi‑year growth targets.
Negative Factors
Ongoing GAAP losses and negative returns
Despite EBITDA progress, persistent GAAP losses and negative ROE indicate the company has not yet converted scale into consistent GAAP profitability. This limits retained earnings, constrains capital allocation flexibility, and means results remain sensitive to execution misses.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth & commercial momentum
Sustained, high‑single to double‑digit revenue growth driven by new launches (DESMODA, HEMANGEOL) and stronger core sales signals scalable commercial execution. Durable revenue expansion supports reinvestment, better leverage of fixed costs, and underpins multi‑year growth targets.
Read all positive factors
Eton Pharmaceuticals (ETON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$865.32M
Dividend YieldN/A
Average Volume (3M)432.27K
Price to Earnings (P/E)―
Beta (1Y)0.80
Revenue Growth79.89%
EPS Growth68.13%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding27,392,359
10 Day Avg. Volume355,236
30 Day Avg. Volume432,270
Financial Highlights & Ratios
PEG Ratio-7.42
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue9.51
Enterprise Value/Gross Profit17.36
Enterprise Value/Ebitda191.23
Forecast
1Y Price Target
$48.50Price Target Upside93.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.8
Revenue Forecast (FY)$113.39M
Eton Pharmaceuticals Business Overview & Revenue Model
Company Description
Eton Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on the invention and market introduction of medical treatments for rare diseases. Its current product lineup features Biorphen and Rezipres, both ph...
How the Company Makes Money
Eton Pharmaceuticals primarily makes money by selling FDA-approved prescription drugs. Revenue is generated from product sales to pharmaceutical wholesalers, specialty pharmacies, hospitals, and other healthcare channels that purchase Eton’s brand...
Eton Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum: record product revenue (73% YoY), successful launches of DESMODA and HEMANGEOL, raised full‑year guidance (> $120M), improving adjusted EBITDA and multiple high‑value pipeline milestones (INCRELEX label study cleared, ET‑700 and Amglidia progress). Operational scalability was highlighted by relatively modest G&A growth versus revenue growth. Key risks discussed include launch execution and reimbursement uncertainty for HEMANGEOL (large portion of volume potentially near‑zero revenue), modest margin dilution from ex‑U.S. INCRELEX shipments, higher recurring FDA program fees, and near‑term cash impacts from the HEMANGEOL acquisition. On balance, the positive commercial performance, upgraded guidance, and clear pipeline catalysts outweigh the near‑term uncertainties reported.Positive Updates
Record Quarterly Product Sales and Strong YoY Growth
Product sales and royalty revenue were $24.3M in Q1 2026, representing a 73% year-over-year increase (Q1 2025 product sales $14.0M). Total revenue for the quarter increased 40% to $24.3M versus $17.3M in Q1 2025.
Negative Updates
HEMANGEOL Launch Uncertainties and Near‑Term Revenue Headwinds
HEMANGEOL launched mid‑March/May with a complex transfer of thousands of patients to a single specialty pharmacy; revenue contribution to Q2 expected to be limited and sizable contribution anticipated to begin in Q3. Management estimates ~60%–65% of HEMANGEOL volume may be near $0 revenue (patient assistance/government patients), implying an estimated average net price of ~$8,000–$10,000 per full course — this mix creates uncertainty in near‑term net pricing and revenue.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Product Sales and Strong YoY Growth
Product sales and royalty revenue were $24.3M in Q1 2026, representing a 73% year-over-year increase (Q1 2025 product sales $14.0M). Total revenue for the quarter increased 40% to $24.3M versus $17.3M in Q1 2025.
Read all positive updates
Company Guidance
Eton raised full‑year 2026 revenue guidance to exceed $120 million (up from $110M), after Q1 product sales of $24.3M (up 73% YOY) and total revenue of $24.3M (up 40% vs. $17.3M including $3.3M licensing in Q1‑2025); Q1 adjusted EBITDA was $5.7M (24% margin) and the company expects full‑year adjusted EBITDA margin above 30% (targeting 50% by 2028). Management expects adjusted gross margin of at least 70% in 2026 (67% in Q1; adjusted gross profit $16.2M or 67% of revenue) and 75–80% in coming years; GAAP G&A was $10.4M (adjusted G&A $9.0M), R&D spending for 2026 to be above $7.8M but less than $10M. Cash from operations was $7.4M in Q1, cash on hand $19.7M after a $14M HEMANGEOL acquisition and amendment of a $30M credit facility (rate down ~200 bps); HEMANGEOL revenue is expected to be limited in Q2 with sizable contribution beginning in Q3, with an estimated average net price per full ~6‑month course of ~$8,000–$10,000 (with ~60–65% of volume near $0 revenue); DESMODA peak sales potential $30–50M; ET‑700 potential >$100M peak (pilot topline in H2‑2026); INCRELEX label study to start H2‑2026 (≈30 patients over 5 years) and could expand the U.S. market ~5x if successful; KHINDIVI supplemental filing targeted Q3‑2026 with potential approval in Q2‑2027, and Amglidia NDA planned for Q4‑2026—all supporting the longer‑term targets of a $200M run rate by end‑2027 and $500M revenue by 2030.Eton Pharmaceuticals Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.93M | 79.95M | 39.01M | 31.64M | 21.25M | 21.83M |
| Gross Profit | 47.61M | 42.74M | 23.41M | 21.06M | 14.32M | 19.21M |
| EBITDA | 4.32M | 4.27M | -657.00K | 212.00K | -7.25M | -1.49M |
| Net Income | -1.48M | -4.60M | -3.82M | -936.00K | -9.02M | -1.96M |
Balance Sheet | ||||||
| Total Assets | 97.71M | 92.11M | 76.12M | 31.74M | 25.03M | 27.46M |
| Cash, Cash Equivalents and Short-Term Investments | 19.66M | 25.94M | 14.94M | 21.39M | 16.30M | 14.41M |
| Total Debt | 12.25M | 31.02M | 29.99M | 5.40M | 6.52M | 6.70M |
| Total Liabilities | 67.09M | 65.96M | 51.70M | 16.26M | 11.95M | 9.84M |
| Stockholders Equity | 30.61M | 26.15M | 24.43M | 15.48M | 13.08M | 17.63M |
Cash Flow | ||||||
| Free Cash Flow | 15.43M | 10.19M | 943.00K | 6.04M | 2.03M | -7.98M |
| Operating Cash Flow | 15.84M | 10.52M | 969.00K | 6.82M | 4.82M | -4.72M |
| Investing Cash Flow | -15.41M | -333.00K | -40.01M | -775.00K | -2.79M | -2.56M |
| Financing Cash Flow | 1.81M | 815.00K | 32.59M | -957.00K | -134.00K | 391.00K |
Eton Pharmaceuticals Technical Analysis
Positive
25.04
Price Trends
28.39
Positive
23.21
Positive
20.41
Positive
Market Momentum
0.62
Positive
57.32
Neutral
83.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ETON, the sentiment is Positive. The current price of 25.04 is below the 20-day moving average (MA) of 31.03, below the 50-day MA of 28.39, and above the 200-day MA of 20.41, indicating a bullish trend. The MACD of 0.62 indicates Positive momentum. The RSI at 57.32 is Neutral, neither overbought nor oversold. The STOCH value of 83.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ETON.
Eton Pharmaceuticals Risk Analysis
Eton Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Eton Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eton Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $865.32M | ― | -5.68% | ― | 79.89% | 68.13% | |
55 Neutral | $1.06B | -8.78 | -63.58% | ― | -61.87% | 10.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $344.31M | ― | -232.50% | ― | -43.96% | -78.31% | |
50 Neutral | $571.36M | -6.81 | -32.33% | ― | ― | 38.99% | |
49 Neutral | $1.69B | -19.10 | -24.50% | ― | ― | -0.43% |
* Healthcare Sector Average
ETON
Eton Pharmaceuticals
31.59
17.42
122.94%
RGNX
RegenXBio
6.66
-2.50
-27.29%
TECX
Tectonic Therapeutic
30.28
8.73
40.51%
ABSI
AbSci
6.80
3.98
141.13%
MBX
MBX Biosciences, Inc.
35.51
25.01
238.19%
Eton Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Eton Shareholders Back Board Nominees and Auditor Selection
Positive
Jun 9, 2026
Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026, where shareholders elected director nominees Jenn Adams and Charles J. Casamento to new three-year terms on the board. Stockholders also ratified th...
Business Operations and Strategy
Eton Pharmaceuticals Secures U.S. Rights to IMPAVIDO
Positive
May 19, 2026
On May 18, 2026, Eton Pharmaceuticals entered a supply and distribution agreement with an affiliate of Knight Therapeutics for exclusive U.S. commercialization rights to IMPAVIDO (miltefosine), the first and only FDA-approved oral therapy for cert...
Business Operations and StrategyProduct-Related Announcements
Eton Pharmaceuticals Relaunches HEMANGEOL With Exclusive Distribution
Positive
May 1, 2026
On May 1, 2026, Eton Pharmaceuticals announced the relaunch of HEMANGEOL (propranolol) Oral Solution, the only FDA-approved treatment for infantile hemangioma, through an exclusive U.S. distribution arrangement with Anovo Specialty Pharmacy. The c...
Business Operations and StrategyProduct-Related Announcements
Eton Starts Pilot Trial of ET-700 for Wilson Disease
Positive
Apr 27, 2026
On April 27, 2026, Eton Pharmaceuticals announced that the first patient had been dosed in a pilot clinical study of ET-700, its proprietary extended-release zinc acetate formulation for Wilson disease. Conducted at Aarhus University Hospital in D...
Business Operations and StrategyExecutive/Board Changes
Eton Pharmaceuticals Announces New Chief Financial Officer Appointment
Positive
Apr 16, 2026
On April 16, 2026, Eton Pharmaceuticals announced that experienced pharmaceutical finance executive Judith “Judy” Matthews had been appointed Executive Vice President, Accounting and Finance, and would assume the role of Chief Financia...
Business Operations and StrategyPrivate Placements and Financing
Eton Pharmaceuticals Amends Credit Agreement, Eases Debt Terms
Positive
Apr 15, 2026
On April 9, 2026, Eton Pharmaceuticals, Inc. amended its credit agreement with SWK Funding LLC, reducing the interest rate from SOFR plus 6.75% to SOFR plus 6.55% and lowering the SOFR floor from 5.0% to 2.75%. The company also extended the intere...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.